APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Targeted Peptide Weight Loss Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Growth and Trends Forecast to 2032

Report ID 173995420127 December 2025122 pages

Choose your research edition.

Industry ResearchGLP-1 Targeted Peptide Weight Loss Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Targeted Peptide Weight Loss Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global GLP-1 Targeted Peptide Weight Loss Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global GLP-1 Targeted Peptide Weight Loss Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The GLP-1 Targeted Peptide Weight Loss Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global GLP-1 Targeted Peptide Weight Loss Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to GLP-1 Targeted Peptide Weight Loss Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global GLP-1 Targeted Peptide Weight Loss Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

GLP-1 Targeted Peptide Weight Loss Drugs Market by Company

Chugai Pharmaceutical

Benemae Pharmaceutical

Qilu Pharmaceutical

Jiuyuan Gene Engineering

Huadong Medicine

Zealand Pharma

The General Hospital Corp

Sanofi-Aventis

QuiaPEG Pharmaceuticals Ab

Orbis Biosciences

Novo Nordisk

Nano Precision Medical

Nanexa AB

Lexaria Bioscience

iX Biopharma

Intarcia Therapeutics

HIKMA PHARMS

Eli Lilly

Baxter Pharmaceutical

Astra Zeneca

Amylin Pharmaceuticals

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type

Oral

Injection

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application

Hospital

Clinic

Others

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Table 2. Major Company of Injection Table 3. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Type (2021-2026) & (US$/Unit) Table 9. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2027-2032) & (K Units) Table 10. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Type (2027-2032) & (US$/Unit) Table 14. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 15. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 17. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 21. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends Table 25. GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers Table 26. GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges Table 27. GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints Table 28. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Market Share by Company (2021-2026) Table 30. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Company (2021-2026) & (K Units) Table 31. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Share by Company (2021-2026) Table 32. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global GLP-1 Targeted Peptide Weight Loss Drugs Major Company Production Sites and Headquarters Table 35. Global GLP-1 Targeted Peptide Weight Loss Drugs Company, Product Type & Application Table 36. Global GLP-1 Targeted Peptide Weight Loss Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global GLP-1 Targeted Peptide Weight Loss Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2026) & (K Units) Table 41. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Application (2021-2026) & (US$/Unit) Table 56. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global GLP-1 Targeted Peptide Weight Loss Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 62. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 64. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 68. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Chugai Pharmaceutical Company Information Table 72. Chugai Pharmaceutical Business Overview Table 73. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 75. Chugai Pharmaceutical Recent Development Table 76. Benemae Pharmaceutical Company Information Table 77. Benemae Pharmaceutical Business Overview Table 78. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 80. Benemae Pharmaceutical Recent Development Table 81. Qilu Pharmaceutical Company Information Table 82. Qilu Pharmaceutical Business Overview Table 83. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 85. Qilu Pharmaceutical Recent Development Table 86. Jiuyuan Gene Engineering Company Information Table 87. Jiuyuan Gene Engineering Business Overview Table 88. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 90. Jiuyuan Gene Engineering Recent Development Table 91. Huadong Medicine Company Information Table 92. Huadong Medicine Business Overview Table 93. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 95. Huadong Medicine Recent Development Table 96. Zealand Pharma Company Information Table 97. Zealand Pharma Business Overview Table 98. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 100. Zealand Pharma Recent Development Table 101. The General Hospital Corp Company Information Table 102. The General Hospital Corp Business Overview Table 103. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 105. The General Hospital Corp Recent Development Table 106. Sanofi-Aventis Company Information Table 107. Sanofi-Aventis Business Overview Table 108. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 110. Sanofi-Aventis Recent Development Table 111. QuiaPEG Pharmaceuticals Ab Company Information Table 112. QuiaPEG Pharmaceuticals Ab Business Overview Table 113. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 115. QuiaPEG Pharmaceuticals Ab Recent Development Table 116. Orbis Biosciences Company Information Table 117. Orbis Biosciences Business Overview Table 118. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 120. Orbis Biosciences Recent Development Table 121. Novo Nordisk Company Information Table 122. Novo Nordisk Business Overview Table 123. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 125. Novo Nordisk Recent Development Table 126. Nano Precision Medical Company Information Table 127. Nano Precision Medical Business Overview Table 128. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 130. Nano Precision Medical Recent Development Table 131. Nanexa AB Company Information Table 132. Nanexa AB Business Overview Table 133. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 135. Nanexa AB Recent Development Table 136. Lexaria Bioscience Company Information Table 137. Lexaria Bioscience Business Overview Table 138. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 140. Lexaria Bioscience Recent Development Table 141. iX Biopharma Company Information Table 142. iX Biopharma Business Overview Table 143. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 145. iX Biopharma Recent Development Table 146. Intarcia Therapeutics Company Information Table 147. Intarcia Therapeutics Business Overview Table 148. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 150. Intarcia Therapeutics Recent Development Table 151. HIKMA PHARMS Company Information Table 152. HIKMA PHARMS Business Overview Table 153. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 155. HIKMA PHARMS Recent Development Table 156. Eli Lilly Company Information Table 157. Eli Lilly Business Overview Table 158. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 160. Eli Lilly Recent Development Table 161. Baxter Pharmaceutical Company Information Table 162. Baxter Pharmaceutical Business Overview Table 163. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 165. Baxter Pharmaceutical Recent Development Table 166. Astra Zeneca Company Information Table 167. Astra Zeneca Business Overview Table 168. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 170. Astra Zeneca Recent Development Table 171. Amylin Pharmaceuticals Company Information Table 172. Amylin Pharmaceuticals Business Overview Table 173. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 175. Amylin Pharmaceuticals Recent Development Table 176. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 177. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 178. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2026) Table 179. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 180. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share Forecast by Country (2027-2032) Table 181. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026) & (US$ Million) Table 183. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country (2021-2026) Table 184. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Share Forecast by Country (2027-2032) Table 186. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 187. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 188. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2026) Table 189. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 190. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share Forecast by Country (2027-2032) Table 191. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026) & (US$ Million) Table 193. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country (2021-2026) Table 194. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Share Forecast by Country (2027-2032) Table 196. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 197. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 198. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2026) Table 199. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 200. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share Forecast by Country (2027-2032) Table 201. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 202. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026) & (US$ Million) Table 203. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country (2021-2026) Table 204. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 205. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Share Forecast by Country (2027-2032) Table 206. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 207. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 208. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2026) Table 209. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 210. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share Forecast by Country (2027-2032) Table 211. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 212. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026) & (US$ Million) Table 213. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country (2021-2026) Table 214. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 215. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Share Forecast by Country (2027-2032) Table 216. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 217. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 218. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2026) Table 219. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 220. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share Forecast by Country (2027-2032) Table 221. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 222. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026) & (US$ Million) Table 223. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country (2021-2026) Table 224. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 225. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Share Forecast by Country (2027-2032) Table 226. Key Raw Materials Table 227. Raw Materials Key Suppliers Table 228. GLP-1 Targeted Peptide Weight Loss Drugs Distributors List Table 229. GLP-1 Targeted Peptide Weight Loss Drugs Customers List Table 230. Research Programs/Design for This Report Table 231. Authors List of This Report Table 232. Secondary Sources Table 233. Primary Sources List of Figures Figure 1. GLP-1 Targeted Peptide Weight Loss Drugs Image Figure 2. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (2021-2032) & (K Units) Figure 5. Oral Image Figure 6. Global Oral Sales YoY Growth (2021-2032) & (K Units) Figure 7. Injection Image Figure 8. Global Injection Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Type 2025 VS 2032 Figure 11. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 GLP-1 Targeted Peptide Weight Loss Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Application 2025 VS 2032 Figure 31. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chugai Pharmaceutical
  • Benemae Pharmaceutical
  • Qilu Pharmaceutical
  • Jiuyuan Gene Engineering
  • Huadong Medicine
  • Zealand Pharma
  • The General Hospital Corp
  • Sanofi-Aventis
  • QuiaPEG Pharmaceuticals Ab
  • Orbis Biosciences
  • Novo Nordisk
  • Nano Precision Medical
  • Nanexa AB
  • Lexaria Bioscience
  • iX Biopharma
  • Intarcia Therapeutics
  • HIKMA PHARMS
  • Eli Lilly
  • Baxter Pharmaceutical
  • Astra Zeneca
  • Amylin Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 GLP-1 Targeted Peptide Weight Loss Drugs Market by Type
  6. 1.3.1 Oral
  7. 1.3.2 Injection
  8. 1.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Type
  9. 1.4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends
  2. 2.2 GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers
  3. 2.3 GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges
  4. 2.4 GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by GLP-1 Targeted Peptide Weight Loss Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by GLP-1 Targeted Peptide Weight Loss Drugs Price (2021-2026)
  4. 3.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global GLP-1 Targeted Peptide Weight Loss Drugs Company, Product Type & Application
  7. 3.7 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GLP-1 Targeted Peptide Weight Loss Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GLP-1 Targeted Peptide Weight Loss Drugs Tier 1, Tier 2, and Tier 3
4 GLP-1 Targeted Peptide Weight Loss Drugs Regional Status and Outlook
  1. 4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Historic Market Size by Region
  3. 4.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Forecasted Market Size by Region
  7. 4.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 GLP-1 Targeted Peptide Weight Loss Drugs by Application
  1. 5.1 GLP-1 Targeted Peptide Weight Loss Drugs Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Application
  6. 5.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chugai Pharmaceutical
  2. 6.1.1 Chugai Pharmaceutical Company Information
  3. 6.1.2 Chugai Pharmaceutical Business Overview
  4. 6.1.3 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  6. 6.1.5 Chugai Pharmaceutical Recent Developments
  7. 6.2 Benemae Pharmaceutical
  8. 6.2.1 Benemae Pharmaceutical Company Information
  9. 6.2.2 Benemae Pharmaceutical Business Overview
  10. 6.2.3 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  12. 6.2.5 Benemae Pharmaceutical Recent Developments
  13. 6.3 Qilu Pharmaceutical
  14. 6.3.1 Qilu Pharmaceutical Company Information
  15. 6.3.2 Qilu Pharmaceutical Business Overview
  16. 6.3.3 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  18. 6.3.5 Qilu Pharmaceutical Recent Developments
  19. 6.4 Jiuyuan Gene Engineering
  20. 6.4.1 Jiuyuan Gene Engineering Company Information
  21. 6.4.2 Jiuyuan Gene Engineering Business Overview
  22. 6.4.3 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  24. 6.4.5 Jiuyuan Gene Engineering Recent Developments
  25. 6.5 Huadong Medicine
  26. 6.5.1 Huadong Medicine Company Information
  27. 6.5.2 Huadong Medicine Business Overview
  28. 6.5.3 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  30. 6.5.5 Huadong Medicine Recent Developments
  31. 6.6 Zealand Pharma
  32. 6.6.1 Zealand Pharma Company Information
  33. 6.6.2 Zealand Pharma Business Overview
  34. 6.6.3 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  36. 6.6.5 Zealand Pharma Recent Developments
  37. 6.7 The General Hospital Corp
  38. 6.7.1 The General Hospital Corp Company Information
  39. 6.7.2 The General Hospital Corp Business Overview
  40. 6.7.3 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  42. 6.7.5 The General Hospital Corp Recent Developments
  43. 6.8 Sanofi-Aventis
  44. 6.8.1 Sanofi-Aventis Company Information
  45. 6.8.2 Sanofi-Aventis Business Overview
  46. 6.8.3 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  48. 6.8.5 Sanofi-Aventis Recent Developments
  49. 6.9 QuiaPEG Pharmaceuticals Ab
  50. 6.9.1 QuiaPEG Pharmaceuticals Ab Company Information
  51. 6.9.2 QuiaPEG Pharmaceuticals Ab Business Overview
  52. 6.9.3 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  54. 6.9.5 QuiaPEG Pharmaceuticals Ab Recent Developments
  55. 6.10 Orbis Biosciences
  56. 6.10.1 Orbis Biosciences Company Information
  57. 6.10.2 Orbis Biosciences Business Overview
  58. 6.10.3 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  60. 6.10.5 Orbis Biosciences Recent Developments
  61. 6.11 Novo Nordisk
  62. 6.11.1 Novo Nordisk Company Information
  63. 6.11.2 Novo Nordisk Business Overview
  64. 6.11.3 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  66. 6.11.5 Novo Nordisk Recent Developments
  67. 6.12 Nano Precision Medical
  68. 6.12.1 Nano Precision Medical Company Information
  69. 6.12.2 Nano Precision Medical Business Overview
  70. 6.12.3 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  72. 6.12.5 Nano Precision Medical Recent Developments
  73. 6.13 Nanexa AB
  74. 6.13.1 Nanexa AB Company Information
  75. 6.13.2 Nanexa AB Business Overview
  76. 6.13.3 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  78. 6.13.5 Nanexa AB Recent Developments
  79. 6.14 Lexaria Bioscience
  80. 6.14.1 Lexaria Bioscience Company Information
  81. 6.14.2 Lexaria Bioscience Business Overview
  82. 6.14.3 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  84. 6.14.5 Lexaria Bioscience Recent Developments
  85. 6.15 iX Biopharma
  86. 6.15.1 iX Biopharma Company Information
  87. 6.15.2 iX Biopharma Business Overview
  88. 6.15.3 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  90. 6.15.5 iX Biopharma Recent Developments
  91. 6.16 Intarcia Therapeutics
  92. 6.16.1 Intarcia Therapeutics Company Information
  93. 6.16.2 Intarcia Therapeutics Business Overview
  94. 6.16.3 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  96. 6.16.5 Intarcia Therapeutics Recent Developments
  97. 6.17 HIKMA PHARMS
  98. 6.17.1 HIKMA PHARMS Company Information
  99. 6.17.2 HIKMA PHARMS Business Overview
  100. 6.17.3 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  102. 6.17.5 HIKMA PHARMS Recent Developments
  103. 6.18 Eli Lilly
  104. 6.18.1 Eli Lilly Company Information
  105. 6.18.2 Eli Lilly Business Overview
  106. 6.18.3 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  108. 6.18.5 Eli Lilly Recent Developments
  109. 6.19 Baxter Pharmaceutical
  110. 6.19.1 Baxter Pharmaceutical Company Information
  111. 6.19.2 Baxter Pharmaceutical Business Overview
  112. 6.19.3 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  114. 6.19.5 Baxter Pharmaceutical Recent Developments
  115. 6.20 Astra Zeneca
  116. 6.20.1 Astra Zeneca Company Information
  117. 6.20.2 Astra Zeneca Business Overview
  118. 6.20.3 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  120. 6.20.5 Astra Zeneca Recent Developments
  121. 6.21 Amylin Pharmaceuticals
  122. 6.21.1 Amylin Pharmaceuticals Company Information
  123. 6.21.2 Amylin Pharmaceuticals Business Overview
  124. 6.21.3 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  126. 6.21.5 Amylin Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
  2. 7.1.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
  6. 7.2.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
  2. 8.1.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
  6. 8.2.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
  2. 9.1.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
  2. 10.1.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
  6. 10.2.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
  2. 11.1.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Analysis
  2. 12.1.1 GLP-1 Targeted Peptide Weight Loss Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process
  7. 12.2 GLP-1 Targeted Peptide Weight Loss Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 GLP-1 Targeted Peptide Weight Loss Drugs Distributors
  10. 12.2.3 GLP-1 Targeted Peptide Weight Loss Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst